NASDAQ · AIMD
Healthcare · Biotechnology
$0.62
Down-$0.01 (-1.37%)
Updated Nov 3, 2026, 10:31 AM
SID Score
2.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AIMD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
AIMD closed at $0.62 after 21 trading sessions, down 53.38% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $0.70 | $0.70 | $0.59 | $0.62 | 23.5K |
| Oct 30, 2026 | $0.6898 | $0.6898 | $0.5601 | $0.6286 | 30.56K |
| Oct 29, 2026 | $0.82 | $0.82 | $0.6811 | $0.729 | 60.64K |
| Oct 28, 2026 | $0.82 | $0.82 | $0.7849 | $0.8109 | 4.27K |
| Oct 27, 2026 | $0.81 | $0.8565 | $0.7801 | $0.7946 | 5.33K |
| Oct 26, 2026 | $0.80 | $0.8779 | $0.7825 | $0.7825 | 17.4K |
| Oct 23, 2026 | $0.844 | $0.8689 | $0.785 | $0.8372 | 28.4K |
| Oct 22, 2026 | $0.9244 | $0.968 | $0.8441 | $0.8441 | 32.36K |
| Oct 21, 2026 | $0.9899 | $0.99 | $0.8801 | $0.8801 | 21.01K |
| Oct 20, 2026 | $0.90 | $0.9311 | $0.89 | $0.9003 | 10.2K |
| Oct 19, 2026 | $0.93 | $0.99 | $0.80 | $0.9315 | 73.99K |
| Oct 16, 2026 | $0.97 | $1.0525 | $0.9238 | $0.9238 | 15.67K |
| Oct 15, 2026 | $0.93 | $1.03 | $0.8702 | $0.96 | 68.99K |
| Oct 14, 2026 | $1.09 | $1.09 | $0.9553 | $0.96 | 36.89K |
| Oct 13, 2026 | $1.12 | $1.12 | $1.08 | $1.08 | 32.26K |
| Oct 12, 2026 | $1.21 | $1.21 | $1.10 | $1.14 | 46.68K |
| Oct 9, 2026 | $1.20 | $1.2597 | $1.20 | $1.21 | 17.61K |
| Oct 8, 2026 | $1.24 | $1.28 | $1.1717 | $1.21 | 62K |
| Oct 7, 2026 | $1.26 | $1.28 | $1.22 | $1.2361 | 40.38K |
| Oct 6, 2026 | $1.34 | $1.3431 | $1.29 | $1.29 | 45.02K |
| Oct 5, 2026 | $1.349 | $1.37 | $1.3117 | $1.33 | 30.3K |
The latest Smart Investors Daily articles mentioning AIMD.
Company
Market Activity
Research & News
AIMD research
Company profile and research snapshot.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 30, 2026
The rapid expansion of its real-world dataset strengthens the foundation of the Company's Chemical Intelligence platform, supporting product improvement, deeper customer engagement and future commercial opportunities.Ongoing factory operations connect customer applications with technology development.
Benzinga · Oct 30, 2026
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that its AI Nose platform has accumulated more than 3 billion real-world chemical data points, surpassing three times
Yahoo · Sep 30, 2026
Partner's Written Confirmation Fulfills Payment Conditions; Initial License Fee Payable Within 15 Business DaysHOUSTON, TX / ACCESS Newswire / September 30, 2026 / (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed the required data delivery and technology transfer under its VELDONA® license agreement, triggering a $600,000 initial license payment. The licensing partner confirmed completion in writing on September 29.
Benzinga · Sep 30, 2026
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed the required data delivery and technology transfer under its VELDONA® license agreement,
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AIMD.
